Neuroimmunology Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Neuroimmunology Market 

5.1. COVID-19 Landscape: Neuroimmunology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Neuroimmunology Market, By Disease Type

8.1. Neuroimmunology Market, by Disease Type

8.1.1. Multiple Sclerosis

8.1.1.1. Market Revenue and Forecast

8.1.2. Neuromyelitis Optica Spectrum Disorder (NMOSD)

8.1.2.1. Market Revenue and Forecast

8.1.3. Myasthenia Gravis

8.1.3.1. Market Revenue and Forecast

8.1.4. Autoimmune Encephalitis

8.1.4.1. Market Revenue and Forecast

8.1.5. Guillain-Barré Syndrome (GBS)

8.1.5.1. Market Revenue and Forecast

8.1.6. Chronic Inflammatory Demyelinating Polyneuropathy

8.1.6.1. Market Revenue and Forecast

8.1.7. Neuroinflammatory Disorders

8.1.7.1. Market Revenue and Forecast

8.1.8. Other Neuroimmune Disorders

8.1.8.1. Market Revenue and Forecast

Chapter 9. Global Neuroimmunology Market, By Treatment Type

9.1. Neuroimmunology Market, by Treatment Type

9.1.1. Immunomodulators

9.1.1.1. Market Revenue and Forecast

9.1.2. Immunosuppressants

9.1.2.1. Market Revenue and Forecast

9.1.3. Monoclonal Antibodies

9.1.3.1. Market Revenue and Forecast

9.1.4. Corticosteroids

9.1.4.1. Market Revenue and Forecast

9.1.5. Intravenous Immunoglobulin (IVIG)

9.1.5.1. Market Revenue and Forecast

9.1.6. Plasma Exchange (PLEX)

9.1.6.1. Market Revenue and Forecast

9.1.7. Cell-based Therapies

9.1.7.1. Market Revenue and Forecast

9.1.8. Other Biologic Therapies

9.1.8.1. Market Revenue and Forecast

Chapter 10. Global Neuroimmunology Market, By Mechanism of Action 

10.1. Neuroimmunology Market, by Mechanism of Action

10.1.1. B-cell Targeting Therapies

10.1.1.1. Market Revenue and Forecast

10.1.2. T-cell Modulation

10.1.2.1. Market Revenue and Forecast

10.1.3. Complement Inhibition

10.1.3.1. Market Revenue and Forecast

10.1.4. Cytokine Inhibition

10.1.4.1. Market Revenue and Forecast

10.1.5. Neuroprotection

10.1.5.1. Market Revenue and Forecast

10.1.6. Anti-inflammatory Therapy

10.1.6.1. Market Revenue and Forecast

Chapter 11. Global Neuroimmunology Market, By Route of Administration

11.1. Neuroimmunology Market, by Route of Administration

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast

11.1.2. Injectable

11.1.2.1. Market Revenue and Forecast

11.1.3. Intravenous (IV)

11.1.3.1. Market Revenue and Forecast

11.1.4. Subcutaneous

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Neuroimmunology Market, By End-User

12.1. Neuroimmunology Market, by End-User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast

12.1.2. Specialty Neurology Clinics

12.1.2.1. Market Revenue and Forecast

12.1.3. Research & Academic Institutes

12.1.3.1. Market Revenue and Forecast

12.1.4. Homecare Settings

12.1.4.1. Market Revenue and Forecast

12.1.5. Rehabilitation Centers

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global Neuroimmunology Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Disease Type

13.1.2. Market Revenue and Forecast, by Treatment Type

13.1.3. Market Revenue and Forecast, by Mechanism of Action

13.1.4. Market Revenue and Forecast, by Route of Administration

13.1.5. Market Revenue and Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Disease Type

13.1.6.2. Market Revenue and Forecast, by Treatment Type

13.1.6.3. Market Revenue and Forecast, by Mechanism of Action

13.1.6.4. Market Revenue and Forecast, by Route of Administration

13.1.6.5. Market Revenue and Forecast, by End-User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Disease Type

13.1.7.2. Market Revenue and Forecast, by Treatment Type

13.1.7.3. Market Revenue and Forecast, by Mechanism of Action

13.1.7.4. Market Revenue and Forecast, by Route of Administration

13.1.7.5. Market Revenue and Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Forecast, by Disease Type

13.2.2. Market Revenue and Forecast, by Treatment Type

13.2.3. Market Revenue and Forecast, by Mechanism of Action

13.2.4. Market Revenue and Forecast, by Route of Administration  

13.2.5. Market Revenue and Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Disease Type

13.2.6.2. Market Revenue and Forecast, by Treatment Type

13.2.6.3. Market Revenue and Forecast, by Mechanism of Action

13.2.7. Market Revenue and Forecast, by Route of Administration  

13.2.8. Market Revenue and Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Disease Type

13.2.9.2. Market Revenue and Forecast, by Treatment Type

13.2.9.3. Market Revenue and Forecast, by Mechanism of Action

13.2.10. Market Revenue and Forecast, by Route of Administration

13.2.11. Market Revenue and Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Disease Type

13.2.12.2. Market Revenue and Forecast, by Treatment Type

13.2.12.3. Market Revenue and Forecast, by Mechanism of Action

13.2.12.4. Market Revenue and Forecast, by Route of Administration

13.2.13. Market Revenue and Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Disease Type

13.2.14.2. Market Revenue and Forecast, by Treatment Type

13.2.14.3. Market Revenue and Forecast, by Mechanism of Action

13.2.14.4. Market Revenue and Forecast, by Route of Administration

13.2.15. Market Revenue and Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Forecast, by Disease Type

13.3.2. Market Revenue and Forecast, by Treatment Type

13.3.3. Market Revenue and Forecast, by Mechanism of Action

13.3.4. Market Revenue and Forecast, by Route of Administration

13.3.5. Market Revenue and Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Disease Type

13.3.6.2. Market Revenue and Forecast, by Treatment Type

13.3.6.3. Market Revenue and Forecast, by Mechanism of Action

13.3.6.4. Market Revenue and Forecast, by Route of Administration

13.3.7. Market Revenue and Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Disease Type

13.3.8.2. Market Revenue and Forecast, by Treatment Type

13.3.8.3. Market Revenue and Forecast, by Mechanism of Action

13.3.8.4. Market Revenue and Forecast, by Route of Administration

13.3.9. Market Revenue and Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Disease Type

13.3.10.2. Market Revenue and Forecast, by Treatment Type

13.3.10.3. Market Revenue and Forecast, by Mechanism of Action

13.3.10.4. Market Revenue and Forecast, by Route of Administration

13.3.10.5. Market Revenue and Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Disease Type

13.3.11.2. Market Revenue and Forecast, by Treatment Type

13.3.11.3. Market Revenue and Forecast, by Mechanism of Action

13.3.11.4. Market Revenue and Forecast, by Route of Administration

13.3.11.5. Market Revenue and Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Forecast, by Disease Type

13.4.2. Market Revenue and Forecast, by Treatment Type

13.4.3. Market Revenue and Forecast, by Mechanism of Action

13.4.4. Market Revenue and Forecast, by Route of Administration

13.4.5. Market Revenue and Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Disease Type

13.4.6.2. Market Revenue and Forecast, by Treatment Type

13.4.6.3. Market Revenue and Forecast, by Mechanism of Action

13.4.6.4. Market Revenue and Forecast, by Route of Administration

13.4.7. Market Revenue and Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Disease Type

13.4.8.2. Market Revenue and Forecast, by Treatment Type

13.4.8.3. Market Revenue and Forecast, by Mechanism of Action

13.4.8.4. Market Revenue and Forecast, by Route of Administration

13.4.9. Market Revenue and Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Disease Type

13.4.10.2. Market Revenue and Forecast, by Treatment Type

13.4.10.3. Market Revenue and Forecast, by Mechanism of Action

13.4.10.4. Market Revenue and Forecast, by Route of Administration

13.4.10.5. Market Revenue and Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Disease Type

13.4.11.2. Market Revenue and Forecast, by Treatment Type

13.4.11.3. Market Revenue and Forecast, by Mechanism of Action

13.4.11.4. Market Revenue and Forecast, by Route of Administration

13.4.11.5. Market Revenue and Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Disease Type

13.5.2. Market Revenue and Forecast, by Treatment Type

13.5.3. Market Revenue and Forecast, by Mechanism of Action

13.5.4. Market Revenue and Forecast, by Route of Administration

13.5.5. Market Revenue and Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Disease Type

13.5.6.2. Market Revenue and Forecast, by Treatment Type

13.5.6.3. Market Revenue and Forecast, by Mechanism of Action

13.5.6.4. Market Revenue and Forecast, by Route of Administration

13.5.7. Market Revenue and Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Disease Type

13.5.8.2. Market Revenue and Forecast, by Treatment Type

13.5.8.3. Market Revenue and Forecast, by Mechanism of Action

13.5.8.4. Market Revenue and Forecast, by Route of Administration

13.5.8.5. Market Revenue and Forecast, by End-User

Chapter 14. Company Profiles

14.1. Biogen Inc

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. F. Hoffmann-La Roche Ltd

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Novartis AG

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sanofi S.A.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bristol Myers Squibb

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck KGaA

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Alexion Pharmaceuticals

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. AbbVie Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. UCB Pharma

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Eli Lilly and Company

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms